Innovation

Human MUC5B Promoter-Reporter Construct

University of California System: University of California, Davis - UC Davis
posted on 05/19/2009

Method for Inhibition of MUC5B Expression

Suggested Uses

  • Can be used to identify compounds that regulate MUC5B expression
  • May be useful in the development of therapeutics for airway diseases such as cystic fibrosis, chronic bronchitis, bronchial pneumonia, and asthma

Advantages

The new MUC5B promoter-reporter construct provides the basis for a simple assay to test for compounds that regulate MUC5B expression.


Innovation Details
 

Detailed Description

Mucins are a family of high molecular weight glycoproteins secreted by epithelial cells lining various organs such as the nasal cavity, esophagus, lungs, and eyes. Mucins are a major component of mucus, and serve an important role in protecting and lubricating epithelial surfaces. There are at least twelve mucin genes in humans, with mucin 5B (MUC5B) and mucin 5AC (MUC5AC) being the main components of human airway secretions. The regulation of expression of these genes, particularly MUC5B, is critical for normal airway function. Aberrant expression of the MUC5B gene is linked to excessive mucus secretion and is closely correlated with the pathogenesis of various airway diseases. For example, MUC5B is one of the major components in mucus obtained from patients suffering from cystic fibrosis and asthma. Therefore, inhibition of MUC5B gene expression has therapeutic potential for the treatment of these diseases.

Researchers at the University of California have constructed and characterized a reporter construct under the control of the MUC5B promoter. This construct contains all of the regulatory elements that are involved in the regulation of MUC5B expression. In addition, the reporter gene included in this construct allows a very simple and easy assay to determine the promoter activity of MUC5B in response to various treatments and is amenable to high throughput screening. Therefore, this construct will be useful for screening drug candidates for inhibition of MUC5B expression.

File Number: 11233 


IP Protection

Patent Number(s): 6818446
Copyright: ©2009-2012, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Robin Stears at University of California System: University of California, Davis - UC Davis for more information.

Request more info via email request more info
People

Case Manager:

Robin Stears Robin Stears

Innovations (39)


Download Technology Brief (PDF)


Followed By

Follow this innovation

Icon_avatar

Anne Minnich

Member since
Jul 2011

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

13,115 members 17,510 innovations 176 organizations

Browse

Linda L. Restifo, M.D., Ph.D. - University of Arizona

"I want to say again how happy I am about the iBridge Network mechanism. This seems ideal for NeuronMetrics and I'm very pleased we will be part of this venture."  read more...